Boehringer Ingelheim Launches AI and Machine Learning Center in London to Drive Pharmaceutical Innovation
Boehringer Ingelheim has expanded its global Computational Innovation presence by launching a new center for AI and machine learning in King’s Cross, London, UK. This investment reflects the company's commitment to advancing AI capabilities in pharmaceutical R&D and acknowledges the UK's dedication to AI and the life sciences sector. The addition of London to Computational Innovation's global locations will enhance the understanding of patient outcomes, identify successful biological mechanisms, and accelerate the delivery of innovative therapies to patients with unmet medical needs.
The new center in London joins existing locations in Austria, Germany, and the USA, focusing on AI, machine learning, human genetics, and computational biology. This strategic move will enable Boehringer Ingelheim to leverage the UK's data resources and talent pool in academia, biotechnology, and AI ecosystems to drive innovation for patient benefit. The company's vision is centered on putting patients first and developing new medicines to address high unmet medical needs.
Lord Patrick Vallance, UK Science Minister, commended Boehringer Ingelheim's investment in King’s Cross, emphasizing the role of AI in advancing life sciences discovery. The company's decision to establish a hub in London will contribute to the flourishing innovation landscape in the city, creating highly skilled jobs and supporting efforts to combat diseases. The government's commitment to data-driven innovation in life sciences and healthcare aligns with Boehringer Ingelheim's mission to deliver impactful therapies.
Boehringer Ingelheim, a biopharmaceutical company with a history dating back to 1885, is dedicated to developing innovative therapies in human and animal health. With a focus on areas of high unmet medical need, the company invests significantly in research and development to improve and extend lives. Boehringer's global workforce of approximately 54,300 employees serves over 130 markets, emphasizing sustainability and long-term impact across the value chain.
The establishment of the new AI and machine learning center in London marks a significant milestone for Boehringer Ingelheim's Computational Innovation unit. By leveraging the UK's expertise in AI and data resources, the company aims to accelerate the discovery and development of targeted medicines for patients with unmet medical needs. The London hub will play a crucial role in understanding patient journeys, identifying disease causes, and driving the development of personalized therapies. Learn more about Boehringer Ingelheim's computational innovation efforts on their website.